Business Wire

THALES

Share
Lack of Flexible Software Licensing Costing Vendors, Finds Thales

More than 90% of independent software vendors and intelligent device vendors (ISVs and IDVs) are missing out on revenue because they’re not offering the flexible licensing models customers demand, new research from Thales has revealed. Of those vendors, over half (54%) admit that this is due to their customers requiring more flexible license models.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112005065/en/

This research comes as the software delivery and entitlement management landscape is changing. Surveying more than 400 global ISVs and IDVs, the 2022 Thales State of Software Monetization Report has found that nearly three quarters (74%) of software vendors expect an increase in the delivery of software-as-a-service (SaaS) via the cloud, while two thirds (66%) anticipate increased delivery of software in a hybrid manner that leverages both on-premises and the cloud.

Vendors cited significant benefits gained from approaches like SaaS, with improved user experience (40%) deemed the most important, ahead of better customer value (34%) and increased revenue opportunities (30%). However, the push towards a digital approach also means considerable challenges for vendors when it comes to licensing and entitling their software. In fact, a full 40% of those surveyed admit to experiencing challenges in licensing their solutions across multiple devices, while the same number report struggling with different deployment environments. Over a third (37%) find it hard supporting the growing number of users who work remotely.

Compliance and misuse costing vendors

On top of these challenges, vendors could also lose out due to customer misuse and compromised software. ISVs and IDVs estimated that more than a quarter of their software was unlicensed in the last year.

Nearly all vendors surveyed (90%) say their revenue is directly impacted by licensing agreement violations and are worried that their software might be stolen, tampered with or copied.

It’s clear that vendors need to offer flexible licensing and entitlement management in order to meet customers’ varying needs,” said Jake Fox, Vice President, Software Monetization, Product Engineering & Services at Thales . “In order to take advantage of the increased demand for more choices in deployment, packaging and managing entitlements, vendors must invest in new technologies and ensure their businesses are prepared to offer software in a variety of ways. Those who lead the way with flexible entitlements will gain in market share, while those who do nothing risk being left behind in an increasingly competitive landscape.”

Data use key to improving revenue

In order to execute an effective software monetization and licensing strategy, software vendors will need to better understand how their software is being utilized by end-users. Doing so will drive forward smarter innovation and improvements in products. Fortunately, over half (54%) of vendors plan to take greater advantage of data for business intelligence. The data points that vendors are relying on, focus heavily on feature usage, and include the features users search for most (43%), , least popular features(41%) and the features used most and least often (41%).

Fox continued. “Data should be an essential part of any successful business, but it must be used properly. Data can lay the groundwork for future product development, ensuring the business is investing in the areas that customers are using. On top of that, it can also underpin software growth strategies by enabling businesses to tweak entitlements, agreements and packaging in real-time to suit customer needs, in turn securing maximum return on their investments.”

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.

PLEASE VISIT

Thales Group
Security

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release

MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind

Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release

New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne

NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release

Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an

Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release

First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye